Our Stocks to Watch tomorrow include ACA Capital (OTC: ACAH), Paradigm Medical Industries, Inc. (OTCBB: PMED), International Stem Cell Corporation (OTCBB: ISCO), Telemedicus, Inc. (OTC: TMDI), Ariel Way, Inc. (OTCBB: AWYI) and ROO Group (OTCBB: RGRP).
Visit http://www.otcpicks.com/ to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts
ACA CAPITAL HOLDINGS (OTC: ACAH)
"Up 109.68% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/ACAH.php
ACA Capital is a holding company that provides asset management services and credit protection products to participants in the global credit derivatives markets, structured finance capital markets and public finance capital markets. ACA Capital's asset management services are provided through its asset management subsidiaries, ACA Management, L.L.C. and ACA Capital Management (U.K.) Pte. Limited, and its credit protection products are provided through its "A" rated financial guaranty insurance subsidiary, ACA Financial Guaranty Corporation. ACA Capital Management (U.K.) Pte. Limited is authorized and regulated by the Financial Services Authority. We operate through three strategic business lines: Asset Management, Structured Credit and Public Finance. Each of these businesses relies on our core competencies of credit analysis, transaction structuring, risk management and surveillance. Applying these competencies across our platform allows us to create efficiencies in our operations and to deliver a wide range of services and products to our institutional customers.
ACAH News:
December 19 - Banks in Talks to Bail Out ACA Capital
According to a New York Times report, banks including Merrill Lynch and Bear Stearns are in talks to bail out bond insurer ACA Capital (OTC: ACAH). ACA has guaranteed $26 billion in mortgage securities and could force the banks to take on billions in losses they had insured against, the Times said. How much money would be required to rescue ACA is unclear, the report claims, adding that another possibility would be to relieve ACA of its obligation to post collateral against its insurance contracts if the company is downgraded.
PARADIGM MEDICAL INDUSTRIES (OTCBB: PMED)
"Up 75.00% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/PMED.php
Paradigm Medical Industries, Inc. engages in the design, development, manufacture, and sale of technology surgical and diagnostic eye care products. Its diagnostic products include P55, P2200, and P2500 pachymetric analyzer; P20 and P2000 A-scan biometric ultrasound analyzer; P37, P37-II, and P2700 A/B scan ocular ultrasound diagnostic product; P40 UBM ultrasound biomicroscope; P45 UBM ultrasound biomicroscope; P60 UBM ultrasound biomicroscope; BFA ocular blood flow analyzer and disposables; CT 200 corneal topography system; LD 400 autoperimetry system; and TKS 5000 autoperimetry system. The company's products also comprise Precisionist Thirty Thousand and Photon laser, which have ocular surgery workstation with surgical equipment and disposables. Paradigm's surgical products are systems for use by ophthalmologists to perform surgical treatment procedures to remove cataracts. It markets its products through direct sales representatives, independent sales representatives, and ophthalmic product distributors in the United States, as well as through a network of dealers internationally. The company was founded in 1989 and is based in Salt Lake City, Utah.
PMED News:
December 19 - Paradigm Medical Industries Receives Major LD400 Perimeter Order from Large Optical Chain in United Kingdom
Paradigm Medical Industries, Inc. (OTCBB: PMED), the leader in glaucoma diagnostic and management devices, disclosed it has received an order for 30 Dicon LD400 Visual Fields Analyzers (Perimeters) from one of the largest optical chains in the United Kingdom. The retail value of this order exceeds $250,000. Delivery is scheduled by the end of this year.
The LD400 AutoPerimeter is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.
"This is a significant acceptance of the fact that our LD400 with its patented Kinetic Fixation feature is the most technically advanced Perimeter available today," said Paradigm Medical's Chief Executive Officer, Raymond Cannefax. "Though the LD400 is in the midst of a major technology upgrade, it is obvious that Paradigm Medical's existing VFA technology is superior."
The Company noted that it already has received written commitments for an additional 40-50 LD400 Perimeters from the same UK optical chain, which will also be delivered during the first quarter of 2008. The total retail value of all shipments would exceed $600,000.
Paradigm Medical Industries, Inc., is the leader in Ultrasound devices, and glaucoma detection and management products.
INTERNATIONAL STEM CELL CORPORATION (OTCBB: ISCO)
"Up 68.33% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/ISCO.php
International Stem Cell Corporation, a development stage biotechnology company, through its subsidiary, Lifeline Cell Technology, LLC, focuses on the development of therapeutic and research products. The company is developing stem cells that are comparable in function to, but distinct in derivation from, embryonic stem cells from which cells for human transplant can be derived; techniques to cause those cells to be differentiated into the specific cell types required for transplant; and manufacturing protocols to produce these cells without contamination with animal by-products in compliance with the U.S. Food and Drug Administration requirements. It aims to use human embryonic stem cells for the treatment of various diseases, including diabetes, liver disease, and retinal disease, through cell transplant therapy. The company also develops research products, including specialized cell systems, and media and reagents for use in stem cell and other medical research. It sells its research products to academic institutions, governmental entities, and commercial research companies. The company was founded in 2001 and is based in Oceanside, California.
ISCO News:
December 19 - International Stem Cell Corporation Creates Human Stem Cell Lines That Can Eliminate Immune Rejection by Patients
Discovery is a Step Closer to a Universal Stem Cell Line for Human Therapeutics and Creation of a Global Stem Cell Bank
Scientists at International Stem Cell Corporation (OTCBB: ISCO) have created unique human stem cell lines that make them easily "immune matched" to human beings and could enable the creation of a bank of stem cells that could be used, without rejection, by a majority of the different people and races of the world.
Akin to the concept of finding multiple "universal Type O blood donors", the discovery is significant because it would eliminate the need for harsh immune suppression drugs currently used for cell transplant therapy. This may open the door to cell transplant therapy for diseases such as juvenile diabetes where the use of immune suppressant drugs is harmful to the patient.
The findings are outlined in a scientific peer review paper entitled "HLA Homozygous Stem Cell Lines Derived from Human Parthenogenetic Blastocysts" which was announced in the December 19, 2007 online edition of Cloning and Stem Cells Journal at:
www.liebertonline.com/doi/pdfplus/10.1089/clo.2007.0063.
Of four unique human stem cell lines created, one line identified as hpSC-Hhom-4 was found to be a match with common immune types found in various races across the United States, opening the door to wide application in human therapeutics. The paper reports that for the Hhom-4 line, for example, therapeutic applications could be beneficial for tens of millions of people in the United States alone.
"We are excited about this finding as it moves us closer to being able to cross-match stem cells for human transplant and build a true stem cell bank that could offer on-demand delivery of stem cells matched to a patient's own immune system and eliminate the need for immunosuppressant drugs," said Jeff Krstich, CEO of International Stem Cell Corporation. "Our intent is to begin clinical safety studies in animals immediately and utilize these hpSC-Hhom (or Hhom) cell lines to advance the field of regenerative medicine, as well as to commercialize our cells for cell transplant therapies."
One of the greatest risks with all transplants is immune rejection, notes Jeffrey Janus, Director of Scientific Research and co-author of the paper. "Immune suppressant drugs are usually required that result in a precarious balance that involves intentional compromise of the patient's immune system to keep the body from rejecting the transplant, while still maintaining an immune system strong enough to defend against opportunistic infections and disease."
It is far more complicated in children, he added. "Children are more sensitive to the harsh effects of immune-suppressant drugs, thereby reducing therapeutic options and positive outcomes."
Transplant-based stem cell therapies face the same immune matching challenges as those faced by patients undergoing tissue and organ transplants. This makes ISCO's creation of the Hhom stem cell lines a significant step toward achieving successful donor stem cell transplants.
These new stem cell lines were created by ISCO lead scientist Dr. Elena Revazova using a process called "parthenogenesis", which utilizes unfertilized human eggs and doesn't destroy fertilized human embryos. International Stem Cell Corporation on June 27, 2007 announced that Dr. Revazova, one of the world's leading cell biologists, had led a team in the first deliberate creation of human parthenogenetic stem lines. That breakthrough was outlined in a peer review paper entitled "Patient-Specific Stem Cell Lines Derived from Human Parthenogenetic Blastocysts", and published in Cloning and Stem Cells Journal at www.liebertonline.com/doi/pdfplus/10.1089/clo.2007.0033.
That process then led to the current creation of the Hhom cell lines, which represent a "next major step" advancement of ISCO's original parthenogenetic breakthrough. Data presented shows that the four new stem cell lines function similarly to those derived from fertilized human embryos and have the capacity to differentiate into the three germ layers of the body, meaning they have the ability to become any human cell type. Future work is focused on differentiating the Hhom cell lines into therapeutically useful cells.
Although these Hhom lines are virtually animal contaminant free - a distinction likely to be critical for meeting Federal Drug Administration (FDA) approval for human clinical trials - the biggest advantage is that these parthenogenetically-derived stem cells have a simplified genetic code in the critical "HLA region" of the DNA, the region that gives a cell its immune profile to the outside world. The overall result produces a cell that is more easily matched with the immune systems of a far greater percentage of a population group.
The paper reports that "with proper selection of oocyte donors according to HLA haplotype, and FDA approved manufacturing protocols, it is possible to generate a bank of cell lines whose tissue derivatives collectively could be MHC-matched with a significant number of individuals."
In explaining how the cell lines may be applied in populations worldwide, the paper notes: "It has been suggested that a panel of only ten HLA homozygous human stem cell lines selected for common types can provide a complete HLA-A, HLA-B and HLA-DR match for 37.7% of United Kingdom recipients, and a beneficial match for 67.4%."
In addressing the US population, the paper notes, "...calculations suggest that there are close to 200 common haplotypes per racial group. The hpSC-Hhom-4 line carries one of the most common haplotypes."
"We believe that Hhom lines are ideally suited for establishing a repository - a stem cell bank - of differentiated cells and tissues HLA-matched to population groups, which could be available for immediate clinical application," added Krstich. "ISCO's discovery significantly reduces the number of necessary stem cell lines needed to treat vast numbers of people. Moreover, the process is relatively efficient and reproducible."
The paper reports that aside from regenerative therapy, "a repository of cells and tissues derived from Hhom lines may be invaluable in the treatment of genetic disorders, "...including Alzheimer's disease, diabetes, Graves disease, hemophilia, Huntington's Disease, muscular dystrophy, Parkinson's disease, sickle cell anemia, Phenylketonuria-PKU and Severe Combined Immune Deficiency (SCID)." Scientists must first change or "differentiate" the Hhom stem cells into the proper cell type to cure these diseases, but the Hhom lines should provide the best starting point for these studies.
TELEMEDICUS INCORPORATED (OTC: TMDI)
"Up 66.67% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/TMDI.php
Telemedicus, Inc. owns and commercializes a medical emergency response and communications technology called the Disaster Relief and Emergency Medical Services (DREAMS) in the United States. It primarily offers the Telemedicus DREAMS system for fixed, mobile, and deployable telemedicine applications, which transmits audio, video and a range of patient biometric data to a physician's workstation from a remote location. Telemedicus also offers a service that includes the conversion of mobile vehicles or remote locations into a virtual emergency trauma center. The company was founded in 2001. It was formerly known as Lipid Labs, Inc. and changed its name to Telemedicus, Inc. in September 2007. The company is headquartered in Houston, Texas.
TMDI News:
December 19 - Telemedicus in Final Phase of Pre-Market Launch Testing
Telemedicus, Inc. (OTC: TMDI) will begin final testing of its technology for fixed/remote and ambulance based systems in anticipation of market launch in early 2008.
"This is a big milestone for the company as we commercialize this exciting technology. We have completed the base model and unit configurations, and we can now add peripherals to the base system for customers who want more features. Because the systems are modular, Telemedicus can launch multiple platforms and support them in the field," said Thomas Cloud, CEO of Telemedicus.
Telemedicus' Disaster Relief and Emergency Medical Services DREAMS(tm) technology turns practically any ambulance or medical transportation vehicle into a mobile trauma center. The doctor is able to provide treatment immediately through the medical technician because the doctor can see the patient and diagnostic data through the Telemedicus system.
The design and development of the next generation of this life saving technology will be completed by Texas A&M, the original developers of the DREAMS(tm) technology. The next generation of medical technology is coming to your neighborhood where a patient will be treated through the Telemedicus DREAMS(tm) technology.
Mr. Cloud explained, "In the near future we can envision a new generation of medical robotics developed by companies like Hansen Medical, Inc. (NASDAQ: HNSN) or Intuitive Surgical, Inc. (NASDAQ: ISRG) controlled by a remote physician through our DREAMS(tm) technology."
ARIEL WAY INCORPORATED (OTCBB: AWYI)
"Up 53.13% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/AWYI.php
Ariel Way, Inc. operates as a technology and services company for global communications, multimedia, and digital signage solutions and technologies. It develops and deploys solutions for business television, digital signage, and interactive media delivered over a combination of satellite, terrestrial, and wireless local networks. The company's digital signage service includes technologies using LCD television and plasma screens to deliver video based messaging directly to consumer audiences. Its integrated multimedia services include music radio, video, and Internet protocol based file transfer for training/catalogs/point of sale integrated with other information to the clients. Ariel Way serves finance-oriented services companies primarily in United Kingdom. The company is headquartered in Vienna, Virginia.
AWYI News:
December 19 - Ariel Way, Inc. Signs MOU With Mason Media Group
Ariel Way, Inc. (OTCBB: AWYI) announced that the Company has signed a Memorandum of Understanding (MOU) with Mason Media Group, LLC, (MMG) a Washington, D.C. based holding company, (www.masonmediagroup.com), that develop, produce, and provide technical services to the broadcast, cable, and film industry with a primary focus on Sports and Entertainment. MMG is also a provider of focused advertising, marketing, entertainment, and audiovisual content capitalizing on the New Media Revolution. Per the agreement, MMG will become a strategic partner to Ariel Way and MMG's top professionals will support Ariel Way's executives with its Digital Signage Business Plan.
Arne Dunhem, Ariel Way president and CEO, said, "We are excited to have Todd Mason and his group as a strategic partner and to have his highly skilled professionals to work with us. They have a terrific experience and capabilities in creating content and HDTV productions that would benefit our advertising clients for our strategy of building a state-of-the-art highly secure Digital Signage Network."
Todd Mason, CEO of MMG, said, "We are looking forward to be part of Ariel Way's Digital Signage strategy. Besides HDTV productions, we believe that we can provide support with focused advertising, marketing, entertainment, and audiovisual content."
ABOUT MASON MEDIA GROUP
Mason Media Group is a holding company, with a mission to expand and invest in unique, top-tier communication and entertainment companies that are revolutionizing the way that people connect and receive information. Mason Media Group identifies new markets and growing companies that build value and equity for its investors and customers. Mason Media Group is poised to become the premier provider of focused advertising, marketing, entertainment, and audiovisual content capitalizing on the New Media Revolution.
MMG companies work with entertainment, political/advocacy, and corporate clients to develop, craft and distribute their message. MMG companies are composed of highly creative and experienced individuals who are leaders in their industry and leverage the latest in new media technology.
ROO GROUP INCORPORATED NEW (OTCBB: RGRP)
"Up 43.88% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/RGRP.php
ROO Group, Inc., through its subsidiaries, operates as a digital media company in the United States. The company provides products and solutions that enable the broadcast of topical video content from its customers' Internet Web sites. It provides technology and content required for video to be played on computers through the Internet, as well as broadcasting platforms, such as set top boxes and wireless devices. ROO Group's activities include the aggregation of video content, media management, traditional and online advertising, hosting, and content delivery. It operates a global network of individual destination portals under the brand ROO TV that enables end users to view video content over the Internet. The company, together its subsidiaries, also services Web sites based in Europe, Australia, the United States, and Asia. In addition, it provides integrated communication solutions, including direct marketing, Internet advertising, and sales promotion. The company sells its products and services through direct sales force and resellers to media and newspaper chains, Internet service providers, and vertical Web sites. ROO Group was founded in 1998 and is based in New York, New York with additional offices in Los Angeles, California; South Melbourne, Australia; and London, the United Kingdom.
RGRP News:
December 19 - ROO Group Announces Strategic Realignment, Appointment of New CEO, Reduction of Workforce and Board of Directors
ROO Group (OTCBB: RGRP) announced that the company has entered into an Executive Management Agreement with KIT Capital pursuant to which it has agreed to appoint Kaleil Isaza Tuzman as Chairman and Chief Executive Officer commencing on January 9th, 2008. Mr. Isaza Tuzman will succeed Robert Petty, who will retain the office of Vice-Chairman of the Board of Directors and Founder.
Mr. Isaza Tuzman, 36, is currently the President and Chief Operating Officer of JumpTV Inc. (TSX, AIM: JTV) where he is responsible for managing the Company's day-to-day operations including global business development, sales, marketing, network operations and product development. As previously announced, he will be stepping down from his operating position at JumpTV on or before January 8th, 2008, but will remain on the board of that company.
ROO also announced that four independent members of the company's board of directors -- Simon Bax, Stephen Palley, Scott Ackerman and Doug Chertok -- have resigned. The Company's Board of Directors is expected to appoint Isaza Tuzman as a Director and the Chairman of the Board of Directors. Upon Mr. Isaza Tuzman's appointment, the Board will consist of three directors which will include current board members Robert Petty and Robin Smyth, Executive Director. In accordance with the terms of an Executive Management Agreement, Isaza Tuzman will have the right to appoint up to four new independent board members to fill vacancies on the Board of Directors, subject to shareholder approval. Isaza Tuzman, is also investing in the Company through an affiliated entity.
Mr. Isaza Tuzman has been brought on to rationalize the existing business and position ROO to become the leader in IPTV infrastructure services-through both organic growth and strategic acquisition. The company is already one of the leading distribution platforms in the online media space and is the premier solution for IP-based Video-on-Demand. The ROO Video Network is watched by millions of viewers and supported by a wide-range of premium advertisers.
"We are very pleased to welcome Kaleil as our new CEO," said Robert Petty, Chairman of ROO. "Kaleil brings the experience and insight needed to lead us through this next stage of growth. He has a proven record of helping companies achieve their fullest potential and we are confident that his deep knowledge of our sector, operational discipline and leadership skills will enable us to generate value for our shareholders."
Mr. Isaza Tuzman stated, "ROO is at an inflection point in its development. The massive growth in the demand for high-value, IP video content, coupled with the need for leading edge platform provisioning puts this company in a very enviable position. I believe that with greater emphasis on exclusive content, TV broadcaster relationships and the best quality distribution tools, ROO will become the leading player in the provisioning of video over the Internet. In my view, a focused B2B strategy is what is needed to build a profitable company in the sector. ROO's commitment to this path -- coupled with our shared vision of potential industry consolidation -- has been critical to my decision to invest in and manage the company."
Under new management, the company plans to:
1. Leverage expertise in international media to expand client and partner base.
2. Reduce costs and implement cost control policies company-wide.
3. Achieve profitability as quickly as possible.
4. Assess and prioritize product development initiatives.
5. Assess corporate branding.
6. Assess and execute strategic acquisitions consistent with the IPTV platform provisioning strategy, including the development of live-streaming and mobile distribution capabilities.
As part of the strategic realignment, ROO also announced today that it has completed a recent reduction of 21% of its workforce. This decision reflects the substantial completion of ROO's platform and automated distribution tools, which have made the company more efficient and reduced staffing needs.
"ROO has now entered a new phase of development," said Robert Petty, Chairman of ROO. "We have substantially automated our operations, allowing us to function as a leaner, more effective company."
Mr. Petty concluded, "I would like to thank our independent board members for their contributions to our organization. As a result of their guidance, we are now a stronger, more efficient company."
As part of the Executive Management Agreement, KIT Capital Ltd., an entity controlled by Kaleil Isaza Tuzman, has been granted the right to purchase up to 51% of the preferred class of shares in the Company at US$0.38 per share. KIT Capital has the option to invest up to US$5 million in common shares of the Company at US$0.16 per share, a 15% premium to the closing price yesterday, December 18th, 2007.
KALEIL ISAZA TUZMAN BIO
Isaza Tuzman is currently the president and COO of JumpTV Inc. (TSX, AIM: JTV), a leader in broadcasting international television and sports over the Internet. He has been a venture capitalist and entrepreneur in digital media since the late '90s, as managing partner of a New York-based merchant bank focusing on new media companies. Isaza Tuzman has served as chairman and CEO of KPE, Inc., a leading digital media services company with clients such as Sony Entertainment, Viacom and Carnival Cruises, and as chairman and CEO of govWorks, Inc., a venture-backed government technology services firm. Isaza Tuzman previously worked at Goldman Sachs, on investment banking and risk arbitrage teams. He has been a member of the Council of Foreign Relations, a U.S. trade representative, and was recently named one of the 100 Most Influential Hispanics by Hispanic Magazine.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
